Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …

Tumor-associated macrophages (TAM) and myofibroblasts are key drivers in cancer that are
associated with drug resistance in many cancers, including pancreatic ductal …

Tumour cells, with stem-like properties, are highly aggressive and often show drug
resistance. Here, we reveal that integrin α v β3 serves as a marker of breast, lung and …

Oncogenic activation of RAS genes via point mutations occurs in 20%–30% of human
cancers. The development of effective RAS inhibitors has been challenging, necessitating …

RAF inhibitors such as vemurafenib and dabrafenib block BRAF–mediated cell proliferation
and achieve meaningful clinical benefit in the vast majority of patients with BRAF V600E …

Aneuploidy is a hallmark of human cancer, yet the molecular mechanisms to cope with
aneuploidy-induced cellular stresses remain largely unknown. Here, we induce …

Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is
associated with dismal outcomes. RAS pathway mutations, mainly NRAS G12D, define the …